FIELD: medicine.
SUBSTANCE: invention relates to medicine and concerns a method for predicting urate nephrolithiasis, where the activity of lactate dehydrogenase (LDH) and gamma-glutamyl transpeptidase (GGT) in urine is determined, followed by calculating the ratio of LDH to GGT activity according to a mathematical formula, and when the LDH/GGT coefficient is higher than 0.17, urate nephrolithiasis is predicted.
EFFECT: invention provides the possibility of predicting urate nephrolithiasis.
1 cl, 1 ex, 3 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| REMEDY FOR THE TREATMENT OF URATE NEPHROLITHIASIS | 2021 |
|
RU2762139C1 |
| PHARMACOLOGICAL AGENT FOR THE TREATMENT OF URATE NEPHROPATHY | 2021 |
|
RU2760949C1 |
| METHOD OF PROTEOMIC CORRECTION OF OXALATE NEPHROLITHIASIS | 2019 |
|
RU2704022C1 |
| PHARMACOLOGICAL AGENT FOR URINARY STONE DISEASE TREATMENT | 2018 |
|
RU2679120C1 |
| AGENT ANTILITAL POSSESSING ANTILITOGENIC ACTION | 2012 |
|
RU2484834C1 |
| METHOD FOR PREDICTION OF URINARY STONE DISEASE | 2010 |
|
RU2451935C1 |
| METHOD FOR DETERMINING THE RISK OF CALCIINATE DEVELOPMENT IN CASE OF CYSTIC OF KIDNEY DISEASES OF CHILDREN | 2017 |
|
RU2649125C1 |
| METHOD OF TOPICAL ENZYMODIAGNOSIS OF DYSMETHABOLIC NEPHROPATHY IN CHILDREN | 0 |
|
SU1544378A1 |
| METHOD FOR REHABILITATION OF PATIENTS WITH RENAL DISEASE | 1999 |
|
RU2177324C2 |
| PROCESS FOR PREPARATION OF A PEPTIDE AGENT WITH ANTILITHOGENIC EFFECT | 2017 |
|
RU2652339C1 |
